We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sandoz announced the US market introduction of SYMJEPI (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.....
Sandoz announced the US Food and Drug Administration (FDA) has approved Symjepi (epinephrine) 0.15 mg Injection for the emergency treatment of allergic reactions in children.